Shionogi & Co., Ltd.

Shionogi Signs Agreement with Denmark on International Industry-Academic
Collaboration Initiatives

Osaka, Japan, April 1, 2011- Shionogi & Co., Ltd. (Head Office: Osaka; CEO and Representative Director:
Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces that it has entered into an agreement with Kingdom
of Denmark (hereafter ‘‘Denmark’’) on the formation of an international network for industry-academic
collaboration in research and development.

The agreement comprises two main undertakings, described below.

1. Matching drug seeds held by Denmark research institutions (including academic institutions and venture
companies) with drug-discovery technology and needs of Shionogi, and establishing cooperative research
relationships with those institutions by embarking on joint research for drug seeds which meets demands.

2. Personnel exchanges with Denmark research institutions to facilitate international human resources
development

Shionogi will continue to expand its network by conducting its SHIONOGI Science Program with academic
institutions and venture companies in Denmark.

This agreement with Denmark on international industry-academic collaboration is a cornerstone of
Shionogi’s efforts to further accelerate the globalization of its activities.

• Messages from institutional representatives

Franz-Michael Skjold Mellbin, Ambassador from Denmark to Japan
It is a great pleasure for me as Ambassador of Denmark to conclude the Memorandum of Understanding
between Shionogi and the Royal Danish Embassy in Tokyo.
Life science, especially bio-pharmaceutical, is one of the important focus areas in Denmark, and Denmark
has a very advanced research and development portfolio. Denmark has been the strategic base for
establishing new business for emerging technologies as well as a global R&D centre in the field of ICT,
energy and environment in addition to life science/biotechnology for a number of European and American
companies.
By concluding this Memorandum of Understanding, I hope Shionogi will access Danish competencies in
bio-pharmaceutical area from research and development to commercialization more smoothly and find
important seeds for their future growth and business expansion.
The Royal Danish Embassy and I would like to strengthen the relationship between Shionogi and Danish
companies, universities, hospitals and other relevant organizations.

Isao Teshirogi, Ph.D., CEO and Representative Director, Shionogi & Co., Ltd.

It is a great pleasure for us to sign a contract with Denmark on the formation of an international network for
industry-academic collaboration in research and development.
Denmark has Medico Valley, one of the famous bioclusters in Europe and many bio-venture companies as
well as academic institutions actively promote research and development on life-science and biotechnology.
We are greatly honored to have an opportunity to form cooperative research relationships and exchange a
wide rage of information, and also discover drug seeds which we will develop to the medicines making a
great contribution to the world. We expect it to foster international human resources by interacting with
researchers with cutting-edge knowledge. Taking an advantage of this opportunity, we will accelerate our
globalization based on research and development.

SHIONOGI Science Program
SHIONOGI Science Program is a newly collaborative industry-academic initiative to find novel drug seeds
globally and develop them for practical use based on Shionogi’s constantly effort to provide medicine of the
best possible kind essential for protection of the health of the people. Since fiscal 2007, Shionogi has
presented its needs under the name of FINDS (PHarma-INnovation Discovery competition Shionogi) and got
many innovative ideas from researchers in Japan to put the ideas into the practical use while working
together.

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light
of the information currently available, assumptions that are subject to risks and uncertainties which could
cause actual results to differ materially from these statements. Risks and uncertainties include general
domestic and international economic conditions such as general industry and market conditions, and
changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with
respect to product-related forward-looking statements. Product risks and uncertainties include, but are not
limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and
concerns about product safety and efficacy; technological advances; adverse outcome of important
litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing
products, there are manufacturing and marketing risks, which include, but are not limited to, inability to
build production capacity to meet demand, unavailability of raw materials and entry of competitive products.
The company disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596